MedTrace Logo

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

NCT05363631 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-12-10

No results posted yet for this study

Summary

The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Conditions

Interventions

DRUG

Selenomethionine (SLM)

Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)

DRUG

Axitinib

Axitinib is a small molecule tyrosine kinase inhibitor.

DRUG

Pembrolizumab

Pembrolizumab is a type of immunotherapy

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Mohammed Milhem

    lead OTHER

Principal Investigators

  • Mohammed Milhem, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363631 on ClinicalTrials.gov